Increased Protection Against COVID-19 Symptoms – Medriva

Increased Protection Against COVID-19 Symptoms

The most recent COVID-19 vaccines have shown to provide a notable 54% more protection against symptoms compared to unvaccinated Americans. This is indeed promising news for those who have received the vaccine, indicating a significant level of immunization. The study suggests that the vaccine is effective in preventing symptoms and provides hope for controlling the spread of the virus. But, like any medical intervention, vaccines too come with potential side effects.

According to a new study published in the journal Vaccine, potential links have been discovered between COVID-19 vaccines and neurological, blood, and heart-related conditions. This study, the largest of its kind, found slight increases in conditions such as myocarditis, pericarditis, and Guillain-Barr syndrome. Out of more than 99 million people studied, researchers observed 190 cases of Guillain-Barr Syndrome and 69 cases of hematological conditions. However, the study also highlighted the rareness of side effects and cautioned that an association between the vaccine and adverse side effects does not prove the vaccine caused them.

While the study identified rare cases of myocarditis, pericarditis, Guillain-Barre syndrome, and blood clots after vaccination, health experts emphasize that the risks of developing COVID-19 are far greater than the risks of getting vaccinated. To put it into perspective, as of now, 13.5 billion COVID vaccines have been administered worldwide, with around 71% of the worlds population receiving at least one dose. Studies have indicated that COVID vaccines are effective at preventing severe illness, hospitalizations, and death. The risk of developing these adverse events is much higher when infected with COVID-19 than after getting vaccinated.

A separate study conducted in Iran aimed to explore the short-term side effects of four available COVID-19 vaccines (Sputnik V, Sinopharm, Oxford AstraZeneca, and Covaxin) among healthcare workers. The prevalence of at least one side effect after the first and second dose of the COVID-19 vaccine was 84.6% and 72.9% respectively. Common side effects included injection site pain, myalgia, muscle pain, fever, headache, and chills.

Despite the slight increase in certain health conditions linked to the COVID-19 vaccines, the consensus among health professionals is that the benefits of the vaccines still outweigh the risks. This is especially true when compared to the risks of contracting the virus itself. While its important for researchers to continue monitoring and investigating potential vaccine-related health issues, its equally crucial for the public to understand that the overall risk profile of the vaccines remains very favorable.

Follow this link:

Increased Protection Against COVID-19 Symptoms - Medriva